JPRN-UMIN000006999招募中2 期
Phase II randomized trail of Gemcitabine and Irinotecan in Patients with Platinum Refractory and Resistant Mullerian carcinoma (tailored dose vs optimal dose chemotherapy) - Phase II randomized trail of Gemcitabine and Irinotecan in Patients with Platinum Refractory and Resistant Mullerian carcinoma (tailored dose vs optimal dose chemotherapy)
School of Medicine, Chiba University0 个研究点目标入组 64 人开始时间: 2012年1月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 64
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 79years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1)Patients who have a history of hypersensitivity to gemcitabine and irinotecan. 2)Patients with active infection 3)Patients with severe complications (Heart disease, uncontrolleddiabetes, malignant hypertension, or bleeding tendency) 4)Patients with other cancer within the past 5 years 5)Patients with myocardial infarction within 6 months or angina attack. 6)Patients who are inappropriate to enter this study with any safety reasons,judged by the treating physician.
研究者
相似试验
已完成
不适用
Phase II Clinical Trial of Gemcitabine and Irinotecan for Unresectable and Recurrent Pancreatic Cancernresectable or Recurrent Pancreatic Cancer (PC)JPRN-UMIN000009963Osaka Medical Center for Cancer and CVD40
已完成
1 期
Phase I/II Trail of Gemcitabine and Irinotecan in Patients with Platinum Refractory and Resistant Ovarian cancer.Patients with platinum-refractory and &#8211resistant ovarian cancer ( including fallopian tube, primary peritoneal cancer)JPRN-UMIN000004449School of Medicine, Chiba University25
未知
2 期
Randomized phase II trial of gemcitabine(GEM) and carboplatin (CBDCA) with or without Dexamethasone(Dex) in untreated non-small cell lung cancer (NSCLC).on small cell lung cancerJPRN-UMIN000000547Kyoto Thoracic Oncology Research Group (KTORG)76
已完成
2 期
A randomized phase II study of Gemcitabine or Gemcitabine + S-1 as adjuvant chemotherapy for resected biliary tract cancerBiliary tract cancer (intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder carcinoma)JPRN-UMIN000007244Adjuvant Therapy for BTC Research Group130
进行中（未招募）
2 期
GABARNANCE TrialJPRN-jRCTs031180319Ikeda Masafumi110